Kwality Pharmaceuticals profitability ratios

Per cent unless marked ×
Tap a line for its trendFY24Mar 2024FY23Mar 2023FY22Mar 2022
Returns
——35.0%
19.8%19.7%—
10.9%——
Margins
21.7%24.0%37.7%
15.3%18.1%35.3%
3.1%56.4%—
10.2%10.3%35.4%
——26.3%
—−2.2%1.7%
Additional
——25.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

KPL₹3,680.60

Kwality Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHMAKERSLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOC
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
Returns
Return on Assets35.03——
Return on Capital Employed—19.6719.78
Return on Invested Capital——10.91
Margins
EBITDA Margin37.6524.0221.69
Operating Margin35.3118.0815.34
Incremental Operating Margin—56.413.12
Pretax Margin35.4410.2610.24
Net Income Margin26.32——
FCF Margin1.73-2.19—
Additional
Effective Tax Rate25.53——
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.